Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Bronchiolitis Obliterans Syndrome - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
This "Bronchiolitis Obliterans Syndrome - Pipeline Insight, 2024" report provides comprehensive insights about 6+ companies and 7+ pipeline drugs in Bronchiolitis Obliterans Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bronchiolitis Obliterans Syndrome pipeline landscape is provided which includes the disease overview and Bronchiolitis Obliterans Syndrome treatment guidelines. The assessment part of the report embraces, in depth Bronchiolitis Obliterans Syndrome commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bronchiolitis Obliterans Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Bronchiolitis Obliterans Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Bronchiolitis Obliterans Syndrome.
Bronchiolitis Obliterans Syndrome Emerging Drugs Chapters
This segment of the Bronchiolitis Obliterans Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Bronchiolitis Obliterans Syndrome Emerging Drugs
Liposomal Cyclosporine A: Zambon
Liposomal Cyclosporine A for Inhalation (LCsAi) is a novel liposomal formulation of cyclosporine A developed for inhaled delivery to the lungs. Calcineurin inhibitors (CNIs), like cyclosporine A, are highly potent immunosuppressive drugs and a cornerstone of lung transplant medicine. LCsAi is administered via a drug-specific investigational eFlow technology nebulizer system (PARI Pharma GmbH). The investigational drug-device combination is designed to deliver LCsAi to the site of disease in the lung. LCsAi received orphan drug designation for the treatment of BOS from the US Food and Drug Administration and European Medicines Agency. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with Bronchiolitis Obliterans Syndrome.
Major Players in Bronchiolitis Obliterans Syndrome
There are approx. 6+ key companies which are developing the therapies for Bronchiolitis Obliterans Syndrome. The companies which have their Bronchiolitis Obliterans Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Zambon.
Bronchiolitis Obliterans Syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bronchiolitis Obliterans Syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bronchiolitis Obliterans Syndrome drugs.
Key Questions
- How many companies are developing Bronchiolitis Obliterans Syndrome drugs?
- How many Bronchiolitis Obliterans Syndrome drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bronchiolitis Obliterans Syndrome?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Bronchiolitis Obliterans Syndrome therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Bronchiolitis Obliterans Syndrome and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Breath Therapeutics
- SCM Lifescience
- OrphAI Therapeutics
Key Products
- Liposomal Cyclosporine A
- SCM-CGH
- LAM-001
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Bronchiolitis Obliterans Syndrome Report Insights
- Bronchiolitis Obliterans Syndrome Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Bronchiolitis Obliterans Syndrome Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/eyu571
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
